Pharmaron acquires Quotient Bioresearch
Deal will enhance service offerings and increase presence in global markets
Pharmaron, a fully integrated contract research organisation (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech R&D, has acquired Quotient Bioresearch. Quotient, a UK-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.
Integrated with Pharmaron’s broader technology platforms in chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development, this acquisition allows the company to provide more comprehensive and integrated services. The addition of the radiochemistry capabilities creates a global leading chemistry platform with a full spectrum of services. Further, the combined entity will generate greater market access in Asia, Europe and the US.
'This acquisition is part of our long-term strategy to grow our services and broaden our technical and geographic footprint to better serve clients throughout the world,' said Dr Boliang Lou, Chairman and Chief Executive Officer of Pharmaron. 'Combining these two companies gives Pharmaron industry-leading custom radiosynthesis capabilities, and further consolidates our leading position in the field of discovery, pre-clinical and clinical DMPK.
'This move will help accelerate the discovery and development of novel drugs for our customers with Pharmaron’s comprehensive and integrated drug research and development engine.'
